Mosaic Activating Mutations in FGFR1 Cause Encephalocraniocutaneous Lipomatosis.

[1]  K. Carman,et al.  Encephalocraniocutaneous lipomatosis, a rare neurocutaneous disorder: report of additional three cases , 2016, Child's Nervous System.

[2]  K. Boycott,et al.  Receptor tyrosine kinase mutations in developmental syndromes and cancer: two sides of the same coin. , 2015, Human molecular genetics.

[3]  Karl J. Dykema,et al.  Oculoectodermal syndrome is a mosaic RASopathy associated with KRAS alterations , 2015, American journal of medical genetics. Part A.

[4]  K. Anderson,et al.  Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy. , 2015, ACS chemical biology.

[5]  S. Braddock,et al.  Grade II pilocytic astrocytoma in a 3‐month‐old patient with encephalocraniocutaneous lipomatosis (ECCL): Case report and literature review of low grade gliomas in ECCL , 2015, American journal of medical genetics. Part A.

[6]  M. Zucchetti,et al.  Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  A. V. van Wijnen,et al.  FGFR1 Signaling Stimulates Proliferation of Human Mesenchymal Stem Cells by Inhibiting the Cyclin‐Dependent Kinase Inhibitors p21Waf1 and p27Kip1 , 2013, Stem cells.

[8]  A. Bellacosa.  Developmental disease and cancer: Biological and clinical overlaps , 2013, American journal of medical genetics. Part A.

[9]  H. Brandling-Bennett,et al.  An Infant with an Alopecic Plaque on the Scalp and Ocular Choristomas: Case Presentation , 2013, Pediatric dermatology.

[10]  Roland Eils,et al.  Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma , 2013, Nature Genetics.

[11]  N. Simonis,et al.  FGFR1 mutations cause Hartsfield syndrome, the unique association of holoprosencephaly and ectrodactyly , 2013, Journal of Medical Genetics.

[12]  Jay Shendure,et al.  Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation , 2013, Genome research.

[13]  Shane S. Sturrock,et al.  Geneious Basic: An integrated and extendable desktop software platform for the organization and analysis of sequence data , 2012, Bioinform..

[14]  I. Petersen,et al.  Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer , 2010, Science Translational Medicine.

[15]  E. Amaya,et al.  FGF signalling: diverse roles during early vertebrate embryogenesis , 2010, Development.

[16]  K. Wang,et al.  Papillary Glioneuronal Tumor Present in a Patient With Encephalocraniocutaneous Lipomatosis: Case Report , 2010, Neurosurgery.

[17]  A. C. Santos,et al.  Low-grade astrocytoma in a child with encephalocraniocutaneous lipomatosis , 2010, Journal of Neuro-Oncology.

[18]  Mingming Jia,et al.  COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer , 2009, Nucleic Acids Res..

[19]  U. Moog.  Encephalocraniocutaneous lipomatosis , 2009, Journal of Medical Genetics.

[20]  M. Mohammadi,et al.  The FGF family: biology, pathophysiology and therapy , 2009, Nature Reviews Drug Discovery.

[21]  K. Anderson,et al.  The Precise Sequence of FGF Receptor Autophosphorylation Is Kinetically Driven and Is Disrupted by Oncogenic Mutations , 2009, Science Signaling.

[22]  稲垣 隆介,et al.  The International Society for Pediatric Neurosurgery に参加して , 2008 .

[23]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[24]  N. Gotoh.  Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins , 2008, Cancer science.

[25]  M. Begleiter,et al.  Expanding the phenotype of oculoectodermal syndrome: Possible relationship to encephalocraniocutaneous lipomatosis , 2007, American journal of medical genetics. Part A.

[26]  G. Mortier,et al.  Encephalocraniocutaneous lipomatosis accompanied by the formation of bone cysts: Harboring clues to pathogenesis? , 2007, American journal of medical genetics. Part A.

[27]  A. Verloes,et al.  Brain anomalies in encephalocraniocutaneous lipomatosis , 2007, American journal of medical genetics. Part A.

[28]  E. Spector,et al.  Familial acanthosis nigricans due to K650T FGFR3 mutation. , 2007, Archives of dermatology.

[29]  Suzanne Schubbert,et al.  Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.

[30]  A. Hartmann,et al.  FGFR3 mutations in epidermal nevi and seborrheic keratoses: lessons from urothelium and skin. , 2007, The Journal of investigative dermatology.

[31]  J. Hurst,et al.  Clinical dividends from the molecular genetic diagnosis of craniosynostosis , 2006, American Journal of Medical Genetics. Part A.

[32]  A. Hunter,et al.  Oculocerebrocutaneous and encephalocraniocutaneous lipomatosis syndromes: Blind men and an elephant or separate syndromes? , 2006, American journal of medical genetics. Part A.

[33]  C. Cremers,et al.  Mutations in different components of FGF signaling in LADD syndrome , 2006, Nature Genetics.

[34]  S. Levy,et al.  Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Shaun K Olsen,et al.  Structural basis for fibroblast growth factor receptor activation. , 2005, Cytokine & growth factor reviews.

[36]  A. Wilkie.  Bad bones, absent smell, selfish testes: The pleiotropic consequences of human FGF receptor mutations , 2005 .

[37]  F. Speleman,et al.  Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome , 2003, Nature Genetics.

[38]  E. Zackai,et al.  Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis. , 2002, American journal of human genetics.

[39]  M. Mohammadi,et al.  Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[41]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[42]  A. N. Meyer,et al.  Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4 , 2000, Oncogene.

[43]  P. J. Thompson,et al.  Antenatal and postnatal findings in encephalocraniocutaneous lipomatosis. , 2000, American journal of medical genetics.

[44]  H. Hamm.  Cutaneous mosaicism of lethal mutations. , 1999, American journal of medical genetics.

[45]  D. Rimoin,et al.  Molecular, radiologic, and histopathologic correlations in thanatophoric dysplasia. , 1998, American journal of medical genetics.

[46]  E. Haan,et al.  A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome. , 1997, American journal of human genetics.

[47]  E. Zackai,et al.  Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromes , 1996, Nature Genetics.

[48]  P. Prinos,et al.  A common FGFR3 gene mutation in hypochondroplasia. , 1995, Human molecular genetics.

[49]  D. Rimoin,et al.  Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3 , 1995, Nature Genetics.

[50]  W. Reardon,et al.  Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome , 1995, Nature Genetics.

[51]  C. Heldin,et al.  Dimerization of cell surface receptors in signal transduction , 1995, Cell.

[52]  W. Reardon,et al.  A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome , 1994, Nature Genetics.

[53]  M. Eccles,et al.  Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2 , 1994, Nature Genetics.

[54]  Arnold Munnich,et al.  Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia , 1994, Nature.

[55]  Sue Malcolm,et al.  Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome , 1994, Nature Genetics.

[56]  D. Church,et al.  Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia , 1994, Cell.

[57]  R. Happle.  Mosaicism in human skin. Understanding the patterns and mechanisms. , 1993, Archives of dermatology.

[58]  J. Hall,et al.  Review and hypotheses: somatic mosaicism: observations related to clinical genetics. , 1988, American journal of human genetics.

[59]  R. Happle.  Cutaneous manifestation of lethal genes , 1986, Human Genetics.

[60]  A. C. Santos,et al.  Are patients with encephalocraniocutaneous lipomatosis at increased risk of developing low-grade gliomas? , 2011, Child's Nervous System.

[61]  F. Newell,et al.  Fibroblast growth factor receptor 1 is a key regulator of early adipogenic events in human preadipocytes. , 2009, American journal of physiology. Endocrinology and metabolism.

[62]  J. Schlessinger,et al.  Signaling by Receptor Tyrosine Kinases , 1993 .